AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis

2.50
Hdl Handle:
http://hdl.handle.net/11287/593978
Title:
AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis
Authors:
Abogunrin, S.; Brand, S.; Desai, K.; Dinet, J.; Gabriel, S.; Harrower, Timothy
Abstract:
BACKGROUND: Cervical dystonia (CD) can be effectively managed by a combination of botulinum neurotoxin A (BoNT-A) and conventional therapy (skeletal muscle relaxants and rehabilitative therapy), but the costs of different interventions in the UK vary. METHODS: A budget impact model was developed from the UK payer perspective with a 5-year time horizon to evaluate the effects of changing market shares of abobotulinumtoxinA, onabotulinumtoxinA, and incobotulinumtoxinA, and best supportive care from the UK payer perspective. Epidemiological and resource use data were retrieved from the published literature and clinical expert opinion. Deterministic sensitivity analyses were performed to determine the parameters most influential on the budgetary findings under base case assumptions. RESULTS: Under base case assumptions, an increased uptake of abobotulinumtoxinA showed an accumulated savings of pound2,250,992 by year 5. Treatment per patient per year with onabotulinumtoxinA and incobotulinumtoxinA costs more when compared to treatment with abobotulinumtoxinA. One-way sensitivity analyses showed that the prevalence of CD, dose per injection of each of the BoNT-As, and time to reinjection of incobotulinumtoxinA and abobotulinumtoxinA influenced the base case findings most. CONCLUSION: There is potential for cost savings associated with the greater use of abobotulinumtoxinA rather than other BoNT-A treatments, permitting more patients to benefit more from effective BoNT-A treatment with a fixed budget.
Citation:
Clinicoecon Outcomes Res. 2015;7:441-9.
Publisher:
Dove Press
Journal:
ClinicoEconomics and outcomes research : CEOR
Issue Date:
9-Sep-2015
URI:
http://hdl.handle.net/11287/593978
DOI:
10.2147/CEOR.S86355
PubMed ID:
26392782
Additional Links:
http://dx.doi.org/10.2147/CEOR.S86355
Note:
This article is available via Open Access. Please click on the 'Additional Link' above to access the full-text.
Type:
Journal Article
Language:
eng
ISSN:
1178-6981
Appears in Collections:
2015 RD&E publications; Neurology

Full metadata record

DC FieldValue Language
dc.contributor.authorAbogunrin, S.en
dc.contributor.authorBrand, S.en
dc.contributor.authorDesai, K.en
dc.contributor.authorDinet, J.en
dc.contributor.authorGabriel, S.en
dc.contributor.authorHarrower, Timothyen
dc.date.accessioned2016-01-19T12:38:12Zen
dc.date.available2016-01-19T12:38:12Zen
dc.date.issued2015-09-09en
dc.identifier.citationClinicoecon Outcomes Res. 2015;7:441-9.en
dc.identifier.issn1178-6981en
dc.identifier.pmid26392782en
dc.identifier.doi10.2147/CEOR.S86355en
dc.identifier.urihttp://hdl.handle.net/11287/593978en
dc.description.abstractBACKGROUND: Cervical dystonia (CD) can be effectively managed by a combination of botulinum neurotoxin A (BoNT-A) and conventional therapy (skeletal muscle relaxants and rehabilitative therapy), but the costs of different interventions in the UK vary. METHODS: A budget impact model was developed from the UK payer perspective with a 5-year time horizon to evaluate the effects of changing market shares of abobotulinumtoxinA, onabotulinumtoxinA, and incobotulinumtoxinA, and best supportive care from the UK payer perspective. Epidemiological and resource use data were retrieved from the published literature and clinical expert opinion. Deterministic sensitivity analyses were performed to determine the parameters most influential on the budgetary findings under base case assumptions. RESULTS: Under base case assumptions, an increased uptake of abobotulinumtoxinA showed an accumulated savings of pound2,250,992 by year 5. Treatment per patient per year with onabotulinumtoxinA and incobotulinumtoxinA costs more when compared to treatment with abobotulinumtoxinA. One-way sensitivity analyses showed that the prevalence of CD, dose per injection of each of the BoNT-As, and time to reinjection of incobotulinumtoxinA and abobotulinumtoxinA influenced the base case findings most. CONCLUSION: There is potential for cost savings associated with the greater use of abobotulinumtoxinA rather than other BoNT-A treatments, permitting more patients to benefit more from effective BoNT-A treatment with a fixed budget.en
dc.language.isoengen
dc.publisherDove Pressen
dc.relation.urlhttp://dx.doi.org/10.2147/CEOR.S86355en
dc.titleAbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysisen
dc.typeJournal Articleen
dc.identifier.journalClinicoEconomics and outcomes research : CEORen
dc.description.noteThis article is available via Open Access. Please click on the 'Additional Link' above to access the full-text.en

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.